Table 1.

Comparative Effectiveness Trials of Non–Vitamin K Oral Anticoagulants Versus Warfarin

	Apixaban (ARISTOTLE)	Dabigatran Low-Dose (RE-LY)	Dabigatran High-Dose (RE-LY)	Rivaroxaban (ROCKET)	Edoxaban Low-Dose (ENGAGE)	Edoxaban High-Dose (ENGAGE)
Number of patients	18 201	18 113		14 264	21 105
Mean CHADS2 score	2.1±1.1	2.1±1.1	2.2±1.2	3.5±0.9	2.8±1.0	2.8±1.0
Medication dose	5 mg BID	110 mg BID	150 mg BID	20 mg daily	30 mg daily	60 mg daily
Stroke or systemic embolism, HR (95% CI)	0.79 (0.66 to 0.95)	0.91 (0.74 to 1.11)	0.66 (0.53 to 0.82)	0.79 (0.66 to 0.96)	1.07 (0.87 to 1.31)	0.79 (0.63 to 0.99)
Ischemic stroke, HR (95% CI)	0.92 (0.74 to 1.13)	1.11 (0.89 to 1.40)	0.76 (0.60 to 0.98)	0.91 (0.73 to 1.13)	1.41 (1.19 to 1.67)	1.00 (0.83 to 1.19)
Total mortality, HR (95% CI)	0.89 (0.80 to 0.998)	0.91 (0.80 to 1.03)	0.88 (0.77 to 1.00)	0.85 (0.70 to 1.02)	0.87 (0.79 to 0.96)	0.92 (0.83 to 1.01)
Intracranial hemorrhage, HR (95% CI)	0.42 (0.30 to 0.58)	0.31 (0.20 to 0.47)	0.40 (0.27 to 0.60)	0.67 (0.47 to 0.93)	0.30 (0.21 to 0.43)	0.47 (0.34 to 0.63)
Major bleeding, HR (95% CI)	0.69 (0.60 to 0.80)	0.80 (0.69 to 0.93)	0.93 (0.81 to 1.07)	1.04 (0.95 to 1.13)	0.47 (0.41 to 0.55)	0.80 (0.71 to 0.91)

HR indicates hazard ratio.